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Abstract
The effect of treatment on health-related quality of life (HRQoL) is an important consideration for patients. In
the LUX-Lung 8 trial, second-line afatinib improved survival outcomes versus erlotinib in patients with squa-
mous cell carcinoma of the lung. In this report, afatinib was also associated with improvements in disease-
related symptoms and HRQoL versus erlotinib, contributing to the overall clinical beneﬁt of afatinib.
Introduction: In the phase III LUX-Lung 8 trial, afatinib signiﬁcantly improved progression-free survival (PFS) and
overall survival (OS) versus erlotinib in patients with squamous cell carcinoma (SCC) of the lung progressing during or
after platinum-based chemotherapy. Patient-reported outcomes (PROs) and health-related quality of life (QoL) in these
patients are presented. Patients and Methods: Patients (n ¼ 795) were randomized 1:1 to oral afatinib (40 mg/d) or
erlotinib (150 mg/d). PROs were collected (baseline, every 28 days until progression, 28 days after discontinuation)
using the European Organization for Research and Treatment of Cancer QoL questionnaire and lung cancer-speciﬁc
module. The percentage of patients improved during therapy, time to deterioration (TTD), and changes over time were
analyzed for prespeciﬁed lung cancer-related symptoms and global health status (GHS)/QoL. Results: Questionnaire
compliance was 77.3% to 99.0% and 68.7% to 99.0% with afatinib and erlotinib, respectively. Signiﬁcantly more
patients who received afatinib versus erlotinib experienced improved scores for GHS/QoL (36% vs. 28%; P ¼ .041)
and cough (43% vs. 35%; P ¼ .029). Afatinib signiﬁcantly delayed TTD in dyspnea (P ¼ .008) versus erlotinib, but not
cough (P ¼ .256) or pain (P ¼ .869). Changes in mean scores favored afatinib for cough (P ¼ .0022), dyspnea1Department of Medical Oncology, Vall d’Hebron University Hospital, Barcelona, Spain
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Patient-Reported Outcomes With Afatinib Versus Erlotinib(P ¼ .0007), pain (P ¼ .0224), GHS/QoL (P ¼ .0320), and all functional scales. Differences in adverse events between
afatinib and erlotinib, speciﬁcally diarrhea, did not affect GHS/QoL. Conclusion: In patients with SCC of the lung,
second-line afatinib was associated with improved prespeciﬁed disease-related symptoms and GHS/QoL versus
erlotinib, complementing PFS and OS beneﬁts with afatinib.
Clinical Lung Cancer, Vol. -, No. -, 1-10 ª 2017 The Authors. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Until recently, approved treatment options for patients with
squamous cell carcinoma (SCC) of the lung have represented a
signiﬁcant unmet medical need, with only the epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib,
and docetaxel, approved in the second-line setting.1 In the past few
years, several new therapies have been approved in this setting,
including immune checkpoint inhibitors (ie, programmed death 1
inhibitors [nivolumab, pembrolizumab] and programmed death
ligand 1 [PD-L1] inhibitor [atezolizumab]), antivascular endothelial
growth factor receptor-2 antibody therapy (ramucirumab, combined
with docetaxel), and the ErbB family blocker afatinib.2-4 This rapid
expansion of treatment options raises a question among clinicians of
which new therapy would provide optimal clinical beneﬁt for
patients with relapsed/refractory disease after progression during or
after chemotherapy.
Afatinib is an irreversible ErbB family blocker.5 In the phase III
LUX-Lung 8 trial, which compared afatinib with erlotinib in
patients with SCC of the lung after treatment failure during or after
platinum-based chemotherapy,6 afatinib improved progression-free
survival (PFS; median 2.6 vs. 1.9 months; hazard ratio [HR],
0.81; P ¼ .0103), overall survival (OS; median 7.9 vs. 6.8 months;
HR, 0.81; P ¼ .0077), and disease control rate (DCR; 50.5% vs.
39.5%; P ¼ .0020) versus erlotinib. The adverse event (AE) proﬁle
in both treatment arms was consistent with previous experience.
Treatment-related Grade 3 diarrhea was more frequent with afatinib
(9.9%) than erlotinib (2.3%) and treatment-related Grade 3 rash/
acne was more frequent with erlotinib (10.4%) than afatinib
(5.9%); otherwise, AE proﬁles were comparable. The rate of dose
reduction because of AEs was higher for afatinib compared with
erlotinib (26.5% vs. 14.2%); however, discontinuation rates
because of AEs were similar between the 2 treatment arms (20.2%
and 17.0% with afatinib and erlotinib, respectively).6 On the basis
of the results of LUX-Lung 8, afatinib was approved by the US
Food and Drug Administration for the treatment of patients with
metastatic squamous nonesmall-cell lung cancer (NSCLC)
progressing after platinum-based chemotherapy, and by the Euro-
pean Medicines Agency for the treatment of locally advanced or
metastatic NSCLC of squamous histology progressing on or after
platinum-based chemotherapy.7,8
With the emergence of several new treatment options for SCC of
the lung,9,10 a key consideration when choosing the most appro-
priate treatment option is the effect on patients’ health-related
quality of life (HRQoL). In patients with NSCLC, disease-related
symptoms, including cough, dyspnea, and pain, are known to
have a profound effect on HRQoL and interfere with daily lifenical Lung Cancer Month 2017activities.11 Up to 68% of patients, when questioned, said they
would prefer a therapy that improved disease-related symptoms
without prolonging life, as opposed to a therapy that improved
survival without symptom beneﬁt.12 On the basis of the importance
of HRQoL, all phase III trials of afatinib in NSCLC have included
fully integrated, comprehensive patient-reported outcome (PRO)
evaluation.13-15
In the LUX-Lung 3 and LUX-Lung 6 studies, ﬁrst-line afatinib
signiﬁcantly improved global health status/quality of life (GHS/
QoL) and prespeciﬁed lung cancer-related symptoms (cough, dys-
pnea, and pain) versus platinum-based chemotherapy in patients
with NSCLC and activating EGFR mutations.13,15 Symptom and
QoL beneﬁt with afatinib has also been shown in patients with
relapsed/refractory NSCLC16 and SCC of the head and neck.17
Furthermore, several studies have shown that tumor progression
in afatinib-treated NSCLC patients is associated with deterioration
in HRQoL, indicating that PROs are a patient-relevant end
point.13,18
In this article we report on the effect of afatinib on prespeciﬁed
PROs and disease-related symptoms compared with erlotinib in
LUX-Lung 8. In addition, because class-related gastrointestinal AEs
associated with TKI therapy are known to have a negative effect on
patients’ QoL, and that diarrhea is frequently observed in afatinib-
treated patients,19 we also report on results from an exploratory
patient substudy of LUX-Lung 8 that assessed the occurrence and
management of diarrhea in individual patients.
Patients and Methods
Study Design and Patients
Details of the LUX-Lung 8 (NCT01523587) study design and
patient eligibility criteria have been published previously.6 Brieﬂy,
this was an open-label, phase III, global, randomized study. Eligible
patients were aged 18 years or older with a diagnosis of advanced-
stage NSCLC of squamous histology, had received at least 4
cycles of platinum-based doublet chemotherapy as ﬁrst-line treat-
ment of stage IIIB/IV NSCLC, with subsequent disease progression,
and had to be eligible for second-line treatment. Patients were
randomized 1:1 to receive either afatinib 40 mg or erlotinib 150 mg
orally once daily. The primary end point was PFS according to a
central independent radiology review (Response Evaluation Criteria
In Solid Tumors version 1.1). The key secondary end point was OS.
Other secondary end points were objective response rate, DCR,
tumor shrinkage, and PROs. The study protocol—designed in
accordance with the Declaration of Helsinki, the International
Conference on Harmonization Guideline for Good Clinical Prac-
tice, and applicable region-speciﬁc regulatory requirements—was
Enriqueta Felip et alapproved by independent ethics committees at each center. All
patients provided written informed consent for trial participation.
Assessment of PROs
The European Organization for Research and Treatment of
Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30)
is comprised of 30 questions and incorporates multi-item scales as
well as single-item measures.20 These include: 1 GHS/QoL scale;
5 functional scales; 3 symptoms scales; and 6 single items to assess
dyspnea, insomnia, appetite loss, constipation, diarrhea, and
ﬁnancial difﬁculties. Each of the multi-item scales includes a
different set of items, and no item occurs in more than 1 scale.21
The lung cancer-speciﬁc module, Quality of Life Questionnaire
Lung Cancer-13 (QLQ-LC13), is comprised of 13 questions and
incorporates 1 multi-item scale to assess dyspnea, as well as a series
of single items to assess pain, coughing, sore mouth, dysphagia,
peripheral neuropathy, alopecia, and hemoptysis.21,22
Patient-reported outcomes were assessed at the ﬁrst visit of each
treatment course, at the end of treatment, and 28 days after treatment
discontinuation. The respective questionnaires were completed by the
patients at the site before they saw the investigator—before clinical
assessment, before any treatment at the clinic, and before the patients
were provided with any new information about their disease status—
to avoid inﬂuencing the questionnaire responses. Information on the
usage of cough, dyspnea, and pain medication was also collected.
An exploratory substudy was undertaken to assess the occurrence
and management of diarrhea at centers that agreed to participate.
Individual patients from these centers who volunteered to partici-
pate were included. Patients were asked to complete a detailed daily
diary on the occurrence of diarrhea and interventions taken. The
objective of the diarrhea substudy was to compare afatinib and
erlotinib in terms of intensity and duration of diarrhea in the ﬁrst 12
weeks of treatment. No formal hypothesis was tested; all analyses
from the substudy are descriptive in nature.
Statistical Analyses
Patient-reported outcome responses were converted to a 0 to 100
scale and analyzed in line with EORTC scoring algorithms.20 The
HRQoL analyses focused on prespeciﬁed symptoms relevant to lung
cancer, speciﬁcally cough (question [Q]1 from QLQ-LC13),
dyspnea (Q3-Q5 from QLQ-LC13), and pain (Q9 and Q19
from QLQ-C30). GHS/QoL (Q29 and Q30 from QLQ-C30) was
also analyzed.
For each of the summary scales and items that measured cough,
dyspnea, and pain, the 2 treatment arms were compared in terms of
3 analyses. First, the proportion of patients who were improved,
deﬁned as an improvement of at least 10 points from baseline scoreTable 1 Symptom Burden at Baseline
Scale Afatin
Cough (Q1 from QLQ-LC13) 39.7 (29
Dyspnea (Q3-Q5 from QLQ-LC13) 28.8 (23
Pain (Q9, Q19 from QLQ-C30) 26.9 (29
Abbreviations: Q ¼ question; QLQ-C30 ¼ Quality of Life Questionnaire C30; QLQ-LC13 ¼ Qualityat any time during the study, was compared. All randomized patients
were included in the denominator. Second, the time to deterioration
(TTD), deﬁned as the time to a 10-point worsening from the
baseline score, was evaluated. Patients who died before deterioration
were analyzed as having deteriorated at the time of death. Patients
with disease progression but without scale deterioration were
censored at the time of the last scale measurement. Patients with no
HRQoL assessments were censored at the day of randomization.
Third, cough, dyspnea, and pain scores over time were assessed using
a mixed-effects growth curve model with the average proﬁle over
time for each end point described by a piecewise linear model
adjusted for the ﬁxed effect race. In addition, all single items and
subscales (functional and symptom) from the EORTC QLQ-C30
and QLQ-LC13 questionnaires were analyzed to summarize the
effect of therapy on the time proﬁle of the measures, and to examine
the consistency of component items with the composite measures.
For functioning scales, a higher score represents a ‘better’ level of
functioning, and deterioration in scales or items related to func-
tioning was deﬁned as a decrease of at least 10 points from baseline.
Because some missing PRO data is inevitable, correlation analyses
were conducted to determine whether missing data because of
patient dropout was associated with patient characteristics or other
factors. Robustness of the primary PRO results from the longitu-
dinal model were assessed by varying data cutoff times and model
truncation times, and sensitivity analyses were carried out using
joint and pattern-mixture models.
Results
Patients
A total of 795 patients were randomized to receive afatinib
(n ¼ 398) or erlotinib (n ¼ 397). Baseline characteristics were
generally similar between the 2 arms and have been reported
previously.6 Brieﬂy, the median age was 64 years, 666 (83.8%)
patients were male, 172 (21.6%) were Eastern Asian, and 728
(91.6%) were ever smokers.
Baseline Scores and Compliance
Baseline PRO questionnaires were completed by 95.5% of
afatinib-treated patients and 95.0% of erlotinib-treated patients.
Baseline symptom scores for cough, dyspnea, and pain were low and
balanced between treatment arms (Table 1). The mean (SD)
baseline score for GHS/QoL was 60.8 (21.0) for the afatinib arm
and 60.2 (21.6) for the erlotinib arm; higher scores reﬂect better
GHS/QoL. Questionnaire completion rates according to treatment
cycle ranged from 77.3% to 99.0% in the afatinib arm and from
68.7% to 99.0% in the erlotinib arm (Figure 1). A similar pro-
portion of patients in both arms completed at least 1 PROMean Symptom Score (SD)
ib Erlotinib
.5) 37.8 (26.3)
.5) 29.7 (23.5)
.2) 29.7 (28.5)
of Life Questionnaire Lung Cancer-13.
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Figure 1 Questionnaire Completion Ratea
aOn the basis of completion of any item in the questionnaire. Cycle 1 is the baseline assessment since questionnaires were completed by patients before seeing the investigator and before any clinical
assessment/treatment.
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4 - Cliquestionnaire after baseline (87.7% of afatinib-treated patients and
89.2% of erlotinib-treated patients). Most patients for whom
HRQoL was not measured after the start of treatment either died or
had disease progression before the second scheduled post-baseline
PRO assessment at day 56.
Patient-Reported Outcomes
Proportion of Patients With Improvements
The percentage of patients reporting improved scores for GHS/
QoL (35.7% vs. 28.3%; P ¼ .041) and cough (43.4% vs. 35.2%;Figure 2 Proportion of Patients With Improvements in Symptoms
Abbreviations: GHS ¼ global health status; OR ¼ odds ratio (afatinib vs. erlotinib); QoL ¼ quality o
nical Lung Cancer Month 2017P ¼ .029) was signiﬁcantly higher with afatinib than erlotinib
(Figure 2). There was no signiﬁcant difference in the proportion of
patients with improved dyspnea (51.3% vs. 44.1%;P¼ .061), or pain
(40.2% vs. 39.2%; P ¼ .775) between treatment arms (Figure 2).
Improvements in individual dyspnea- and pain-related items, as well
as in functional scales of QLQ-C30, are shown in Supplemental
Table 1 in the online version. Afatinib was associated with a signiﬁ-
cant improvement in ‘dyspnea walked’ (34.6% vs. 26.5%; P¼ .022)
but did not signiﬁcantly improve any other individual symptom
items, or functional scales of QLQ-C30, versus erlotinib.f life.
Figure 3 Time to Deterioration of (A) Dyspnea, (B) Cough, (C) Pain
Abbreviation: HR ¼ hazard ratio.
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Figure 4 Time to Deterioration of Symptoms
Abbreviations: GHS ¼ global health status; HR ¼ hazard ratio; Q ¼ question; QLQ-C30 ¼ Quality of Life Questionnaire C30; QLQ-LC13 ¼ Quality of Life Questionnaire Lung Cancer-13;
QoL ¼ quality of life.
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Afatinib signiﬁcantly delayed TTD of dyspnea versus erlotinib
(median 2.6 vs. 1.9 months; P ¼ .008; Figure 3A), with a consistent
pattern of improvement across dyspnea subcategories (Figure 4).
There was no signiﬁcant difference in TTD of cough (4.5 vs. 3.7
months; P ¼ .256; Figure 3B) or pain (2.5 vs. 2.4 months; P ¼ .869;
Figure 3C) between treatment groups. TTD was also similar for GHS/
QoL and functional scales with afatinib versus erlotinib (Figure 4).
Scores Over Time
Scores over time signiﬁcantly favored afatinib over erlotinib for
cough (mean difference ¼ 3.60; P ¼ .0022), dyspnea (mean
difference ¼ 3.25; P ¼ .0007), and pain (mean
difference ¼ 2.72; P ¼ .0224; Figure 5); signiﬁcant improve-
ments over time were also observed for all individual items with the
exception of ‘have pain,’ ‘pain in arm or shoulder,’ and ‘pain in
other parts.’ Signiﬁcant differences in favor of afatinib were observed
for GHS/QoL (mean difference ¼ 1.95; P ¼ .0320) and all func-
tioning scales over time (Figure 5).nical Lung Cancer Month 2017Correlation analyses between missing data, and patient charac-
teristics and treatment, showed a weak positive correlation over the
ﬁrst few weeks of treatment with a baseline Eastern Cooperative
Oncology Group performance status of 1 (see Supplemental Table 2
in the online version), as well as a weak positive correlation with
erlotinib treatment at weeks 12 and 36, indicating that more
erlotinib-treated patients dropped out at these time points relative to
afatinib-treated patients (see Supplemental Table 3 in the online
version). In each treatment arm, weak positive correlations, partic-
ularly during the early weeks of the trial, were associated with
severity of dyspnea and pain symptoms at baseline but not with
severity of cough; worse GHS/QoL score at baseline was also
associated with missing data because of patient dropout
(see Supplemental Table 4 in the online version). When GHS/QoL
and symptoms were examined with respect to the last known
assessment for each measure, the correlations were stronger than
those found versus the baseline assessment, suggesting that the
patterns of missing data for the parameters described do depend on
the observed data (data on ﬁle).
Figure 5 Difference in Mean Scores Over Time for Cough, Dyspnea and Pain (A) and GHS and Functional Scales (B)
Abbreviations: GHS ¼ global health status; Q ¼ question; QLQ-C30 ¼ Quality of Life Questionnaire C30; QLQ-LC13 ¼ Quality of Life Questionnaire Lung Cancer-13; QoL ¼ quality of life.
Enriqueta Felip et alDifferences in mean scores for cough, dyspnea, and GHS/QoL
did not vary when different data cutoffs and truncation points were
used (see Supplemental Figure 1 in the online version), suggesting
the results of the primary PRO analysis were robust. Sensitivity
analyses were conducted using 3 joint models on the basis of time to
treatment termination (censored at time of database lock), and time
to last assessment (either uncensored or censored at time of database
lock) as the time to dropout event. The estimates of treatment effect
consistently favored afatinib over erlotinib for each end point,
supporting the primary PRO analysis conclusions (see Supplemental
Table 5 in the online version). Further, results of sensitivity analyses
on the basis of pattern-mixture models generally reﬂected the
primary PRO analysis (see Supplemental Table 6 in the online
version). Compared with the primary PRO analysis, a stronger
between-treatment difference in favor of afatinib was observed for
cough, suggesting that, at least for this measure, the results of the
primary PRO analysis might be conservative.
Analyses of Individual PRO Items
Status changes (improved, stable, or worsened) in individual
items of QLQ-C30 and QLQ-LC13 are shown in Supplemental
Table 7 in the online version. Afatinib treatment was associated
with a greater percentage of patients with improvements in overall
health rate versus erlotinib (Q29 from QLQ-C30; 43.4% vs.
35.8%; P ¼ .045). There were also trends toward a greaterpercentage of patients with improvements in QoL rate (Q30 from
QLQ-C30; 43.1% vs. 36.0%; P ¼ .060) and ‘felt weak’ (Q12 from
QLQ-C30; 31.2% vs. 24.6%; P ¼ .058) with afatinib versus
erlotinib. Compared with erlotinib, a greater percentage of patients
receiving afatinib had worsening of diarrhea (Q17 from QLQ-C30;
77.2% vs. 54.0%; P ¼ .146) and sore mouth (Q6 from QLQ-
LC13; 60.7% vs. 37.5%; P ¼ .113; see Supplemental Table 7 in
the online version), but the differences were not statistically
signiﬁcant.
Differences in TTD and mean scores over time between treat-
ment arms for individual items of the QLQ-C30 and QLQ-LC13
are shown in Supplemental Figures 2 and 3, respectively, in the
online version. Overall, most individual items tended to favor
afatinib for TTD as well as changes over time. However, as expected
because of the observed AE proﬁles of afatinib and erlotinib in
LUX-Lung 8, the individual items of diarrhea and sore mouth
favored erlotinib.
Patients’ Perspectives on the Effect of Diarrhea
In LUX-Lung 8, the frequency of treatment-related Grade 3/4
diarrhea was higher with afatinib (9.9%/0.5%) than erlotinib
(2.3%/0.3%), although discontinuations because of diarrhea were
low for both treatment arms (4.1% with afatinib and 1.5% with
erlotinib).6 In a small substudy to assess the effect of diarrhea from a
patient’s perspective, a selected subset of 63 patients (afatinibClinical Lung Cancer Month 2017 - 7
Patient-Reported Outcomes With Afatinib Versus Erlotinib
8 - Clin ¼ 36, erlotinib n ¼ 27) consented to providing a detailed diary of
the onset, intensity, and duration of diarrhea (any Grade) in the ﬁrst
12 weeks of the study. The overall incidence of diarrhea was
consistent with that in the main trial population, with 31 (86.1%)
patients in the afatinib arm and 14 (51.8%) patients in the erlotinib
arm reporting diarrhea (see Supplemental Table 8 in the online
version). Seven patients experienced Grade 3 diarrhea in the afatinib
group (median duration: 3 days [range, 2-10]). However, over the
course of the whole 12-week substudy, cases of Grade 3 diarrhea
were intermittent, being experienced on only 1.5% of the total
number of patient-days of treatment. No patients in the substudy
discontinued afatinib treatment because of diarrhea, although 7
patients in the afatinib arm had diarrhea-related dose reductions.
Medication Usage
A smaller proportion of patients in the afatinib group took pain
medication (afatinib 52%; erlotinib 59%; odds ratio, 0.75; 95%
conﬁdence interval, 0.57-1.00; P ¼ .0508), but the difference was
not statistically signiﬁcant. No differences were observed between
treatment groups in the proportion of patients who took medication
for cough or dyspnea.
Discussion
The recent phase III LUX-Lung 8 study showed signiﬁcantly
prolonged PFS and OS with afatinib versus erlotinib in patients
with SCC of the lung after failure during or after platinum-based
chemotherapy.6 As with many oncology trials, PFS was chosen as
the primary end point for LUX-Lung 8 because, unlike OS, it is not
inﬂuenced by differences in subsequent therapies.23 However, it is
important to assess PROs/HRQoL alongside survival outcomes to
validate the clinical meaningfulness of observed improvements in
PFS and to ensure any extended lifespan attained during treatment
is as comfortable as possible for patients.24 Hence, comprehensive
PRO/HRQoL assessments were prespeciﬁed in the LUX-Lung 8
trial to provide an essential component to analysis of the beneﬁt/risk
proﬁle of treatment in conjunction with efﬁcacy and safety
assessments.25
We prespeciﬁed 3 key NSCLC-related symptoms that are re-
ported to matter most to patients: dyspnea, cough, and pain.26
These symptoms can have a profound effect on HRQoL and
interfere with daily life activities in patients with NSCLC, although
symptom burden at baseline was low and balanced between treat-
ment arms in LUX-Lung 8. Three approaches for the analysis of the
prespeciﬁed symptoms were stipulated in the protocol: proportion
of patients with clinically meaningful improvements in each
symptom, analysis of TTD of symptoms, and longitudinal analysis
of symptoms over time. These approaches, also used in previous
afatinib trials,13,15 broadened the perspective of the results and
enhanced their interpretation. Compared with erlotinib, afatinib
treatment was associated with a signiﬁcantly higher number of pa-
tients reporting improved GHS/QoL and cough, a signiﬁcant delay
in TTD of dyspnea, and signiﬁcantly improved mean scores over
time for cough, dyspnea, and pain. These data complement the
consistent beneﬁt observed with afatinib across all efﬁcacy end
points, including OS, PFS, and DCR, in patients with SCC of the
lung who have disease progression during or after platinum-based
chemotherapy. Overall, these ﬁndings are consistent with recentnical Lung Cancer Month 2017results in the second-line setting of recurrent and/or metastatic SCC
of the head and neck, wherein the PFS beneﬁt observed with afa-
tinib over methotrexate was also associated with a signiﬁcant
improvement in PROs.17
The primary analysis of LUX-Lung 8 demonstrated that the
overall tolerability proﬁle was similar between treatment arms;
57.1% and 57.5% of patients experienced Grade  3 AEs with
afatinib and erlotinib, respectively. Permanent treatment discon-
tinuations were also comparable (occurring in 20.2% of afatinib-
treated patients and 17.0% of erlotinib-treated patients), although
dose reductions occurred more frequently with afatinib (26.5%)
than erlotinib (14.2%).6 Furthermore, AEs were consistent with the
mechanism of action of afatinib, including characteristic class-
related gastrointestinal (diarrhea, stomatitis) and cutaneous (rash/
acne) events. As with all TKIs that target EGFR, afatinib is asso-
ciated with diarrhea; the incidence of treatment-related Grade 3/4
diarrhea in LUX-Lung 8 was 9.9%/0.5% with afatinib, compared
with 2.3%/0.3% in the erlotinib arm.6 In the present study, the
increased incidence of diarrhea with afatinib versus erlotinib was
also reﬂected in patients’ responses to the relevant individual items
of QLQ-C30 and QLQ-LC13. A voluntary patient substudy, un-
dertaken in < 10% of the overall trial population, allowed further
patient-level detail to be gathered on the occurrence and manage-
ment of diarrhea. Although the frequency and duration of all-Grade
diarrhea was greater with afatinib than erlotinib, median duration of
Grade  3 diarrhea was 3 days. Overall, cases of Grade  3 diarrhea
were intermittent, being experienced on 1.5% of the total number
of patient-days of treatment. Furthermore, no patients in the sub-
study (compared with 4.1% of patients in the overall population)
discontinued treatment with afatinib because of diarrhea, possibly as
a result of the recommended afatinib dose-reduction scheme that is
speciﬁed in the prescribing information and designed to manage
such AEs.8 Of note, post hoc analyses of LUX-Lung 3,
LUX-Lung 6, and LUX-Lung 7 have shown that dose adjustment of
afatinib does not affect efﬁcacy.27-29 Overall, although diarrhea is a
frequent AE with afatinib, episodes generally appear to be transient
and manageable with antidiarrheal medication and dose modiﬁca-
tion. Consequently, incidence of diarrhea does not affect overall
GHS/QoL, which is improved with afatinib versus erlotinib.
Although several other phase III trials have evaluated the effect of
reversible EGFR inhibitors (ie, erlotinib and geﬁtinib) on cancer-
related symptoms and HRQoL in NSCLC patients, there is an
overall lack of consensus in the ﬁndings, whichmight be related to the
different assessment tools used to capture PROs. In the phase III
BR.21 trial, which also used the well validated QLQ-C30 and QLQ-
LC13 questionnaires, second- or third-line erlotinib signiﬁcantly
improved symptoms and delayed TTD for cough, dyspnea, and pain
versus placebo, reinforcing the appropriateness of these instruments
for detecting improvements in PROs in a second-line treatment
setting.30 However, in the phase III Tarceva in Treatment of
Advanced NSCLC (TITAN) study, there was no signiﬁcant differ-
ence in the TTD of symptoms with second-line erlotinib versus
docetaxel or pemetrexed, on the basis of the Functional Assessment of
Cancer Therapy-Lung (FACT-L) questionnaire.31 Likewise, there is a
lack of consensus regarding the effect of geﬁtinib on HRQoL in
randomized studies. Some phase III trials have shown that signiﬁ-
cantly more patients attain sustained and clinically relevant
Enriqueta Felip et alimprovements in HRQoL with second-line geﬁtinib versus docetaxel
on the basis of the FACT-L total score.32,33 Conversely, the phase III
IRESSA as Second-line Therapy in Advanced NSCLC - KoreA
(ISTANA) trial showed no difference in HRQoL between geﬁtinib
and docetaxel on the basis of FACT-L.34 Although EGFR-TKIs have
shown HRQoL improvements versus standard second-line chemo-
therapy in some studies, to our knowledge, the current study is the
ﬁrst randomized trial to compare PROs between 2 EGFR-targeted
agents in patients with relapsed/refractory SCC. An analysis of
HRQoL outcomes in the phase III CheckMate-017 trial was also
recently reported, showing signiﬁcant improvements from baseline in
patient-reported health status over 48 weeks of treatment with
nivolumab but not docetaxel, on the basis of the European Quality of
Life-5 Dimensions questionnaire; outcomes for speciﬁc lung cancer-
related symptoms have not been reported.35 Similarly, pem-
brolizumab improved HRQoL and prolonged TTD of lung cancer
symptoms compared with docetaxel in patients with previously
treated PD-L1-positive, advanced NSCLC (KEYNOTE-010).36
A number of steps were taken to ensure the validity and
robustness of the PRO results, and data collection was optimized to
ensure their clinical relevance. To avoid bias, patients answered
questions before meeting physicians and completed the question-
naires themselves, with data collected at the ﬁrst visit of each
treatment cycle. In addition, because of the importance of mini-
mizing the occurrence of missing data in PRO analyses,15,37 it is
noteworthy that compliance with questionnaire completion ranged
from 77% to 99% throughout the study for patients treated with
afatinib. This high level of compliance was in line with that
observed in LUX-Lung 3 (87%-99%) and LUX-Lung 6 (approxi-
mately 90%).13,15 The EORTC QLQ-C30 and QLQ-LC13 in-
struments used in this study are well validated, and allow the
accurate assessment of PROs.20,22 However, PRO assessments are
often discontinued at the time of disease progression, meaning that
symptom deterioration beyond progression is not taken into ac-
count by the data, and PRO beneﬁts might be overestimated. In
LUX-Lung 8, this issue was avoided by scheduling a PRO assess-
ment at the follow-up visit, 28 days after study drug discontinua-
tion. Nevertheless, the collection of PRO data after disease
progression also has an effect on data interpretation because of
variations in postprogression treatments. In addition, patients might
have been less inclined to complete questionnaires when feeling
unwell, so the data might under-represent patients with more severe
symptoms. Although differences in questionnaire compliance be-
tween treatment arms have the potential to introduce bias to the
data, in the current study, sensitivity analyses conducted for indi-
vidual disease-related symptoms (eg, cough, dyspnea) and GHS/
QoL using additional data cutoffs and truncation points conﬁrmed
the robustness of the primary PRO analysis results.
Conclusion
In summary, second-line afatinib signiﬁcantly improved symptoms
of cough and GHS/QoL and signiﬁcantly delayed TTD of dyspnea
compared with erlotinib in patients with SCC of the lung. Mean
scores over time also signiﬁcantly favored afatinib over erlotinib for
cough, dyspnea, pain, GHS/QoL, and all functional scales. Differ-
ences in AEs between afatinib and erlotinib were reﬂected in the PRO
outcomes, with a greater proportion of patients in the afatinib armexperiencing worsening diarrhea and sore mouth compared with
erlotinib, although these differences did not appear to affect overall
GHS/QoL. These data, combined with signiﬁcant improvements in
PFS and OS with afatinib, should be taken into account when
considering treatment options for patients with SCC of the lung after
failure during or after platinum-based chemotherapy.
Clinical Practice Points
 Squamous cell carcinoma of the lung remains a disease with high
unmet medical need, particularly for patients with relapsed/re-
fractory disease after platinum-based chemotherapy. Among other
emerging therapeutic options, afatinib was approved in this setting
after showing signiﬁcant improvements in PFS and OS versus
erlotinib in the phase III LUX-Lung 8 trial. Because HRQoL is an
important consideration for cancer patients, the effect of newer
treatments, including afatinib, on PROs of disease-related symp-
toms and GHS might be a key factor in treatment choice.
 In LUX-Lung 8, second-line afatinib was associated with a
signiﬁcantly higher percentage of patients reporting improve-
ments in cough and GHS/QoL, and signiﬁcantly delayed TTD
in dyspnea, versus erlotinib. Mean scores over time also signiﬁ-
cantly favored afatinib for cough, dyspnea, pain, GHS/QoL, and
all functional scales. As expected, because of the observed AE
proﬁles for each agent, PROs for worsening of diarrhea favored
erlotinib over afatinib (nonsigniﬁcant difference). However, ep-
isodes of diarrhea were shown to be transient and manageable,
and did not affect GHS/QoL.
 The improvements in disease-related symptoms and QoL
observed with afatinib versus erlotinib in patients with SCC of
the lung progressing on/after platinum-based chemotherapy
contribute to the overall clinical beneﬁt of afatinib. Combined
with the signiﬁcant improvements in PFS and OS observed with
afatinib versus erlotinib in LUX-Lung 8, and a predictable and
manageable safety proﬁle, these ﬁndings suggest that afatinib is a
favorable treatment option in this setting.Acknowledgments
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Supplemental Figure 1 Differences in Mean Scores for (A) Coughing, (B) Dyspnea, and (C) GHS/QoL in the Primary Analysis and Using
Additional Data Cutoffs and Truncation Points
Abbreviations: GHS ¼ global health status; QoL ¼ quality of life.
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Supplemental Figure 2 Time to Deterioration in Individual Items of (A) QLQ-C30 and (B) QLQ-LC13
Abbreviations: HR ¼ hazard ratio; Q ¼ question; QLQ-C30 ¼ Quality of Life Questionnaire C30; QLQ-LC13 ¼ Quality of Life Questionnaire Lung Cancer-13; QoL ¼ quality of life.
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Supplemental Figure 3 Difference in Mean Scores Over Time in Individual Items of (A) QLQ-C30 and (B) QLQ-LC13
Abbreviations: HR ¼ hazard ratio; Q ¼ question; QLQ-C30 ¼ Quality of Life Questionnaire C30; QLQ-LC13 ¼ Quality of Life Questionnaire Lung Cancer-13.
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Supplemental Table 1 Improvement in GHS/QoL, Prespeciﬁed Symptoms, and Functional Scales of QLQ-C30 and QLQ-LC13
Question
Afatinib Erlotinib
OR Pn Improved, % Stable, % Worsened, % n Improved, % Stable, % Worsened, %
Global Health Status
GHS/QoL 29, 30 QLQ-C30 339 35.7 20.6 43.7 339 28.3 20.9 50.7 1.40 .041
Prespeciﬁed Symptoms
Cough 1 QLQ-LC13 339 43.4 25.4 31.3 341 35.2 29.3 35.5 1.41 .029
Dyspnea 3 to 5 QLQ-LC13 339 51.3 13.3 35.4 340 44.1 10.9 45.0 1.33 .061
Rested 3 QLQ-LC13 339 22.4 46.6 31.0 341 22.0 41.9 36.1 1.02 .897
Walked 4 QLQ-LC13 338 34.6 28.4 37.0 340 26.5 31.5 42.1 1.47 .022
Stairs 5 QLQ-LC13 337 34.7 30.6 34.7 338 33.1 28.7 38.2 1.07 .663
Shortness of breath 8 QLQ-C30 340 35.3 28.8 35.9 342 31.0 29.8 39.2 1.21 .234
Pain 9, 19 QLQ-C30 343 40.2 19.0 40.8 342 39.2 17.5 43.3 1.05 .775
Have pain 9 QLQ-C30 342 32.2 28.4 39.5 342 36.0 24.6 39.5 0.84 .297
Affecting daily activities 19 QLQ-C30 340 27.1 32.9 40.0 337 27.6 31.8 40.7 0.97 .880
Chest 10 QLQ-LC13 337 29.1 41.8 29.1 341 26.7 40.5 32.8 1.13 .489
Arm/shoulder 11 QLQ-LC13 337 25.2 43.9 30.9 339 32.2 39.8 28.0 0.71 .047
Other parts 12 QLQ-LC13 328 24.7 39.9 35.4 326 26.4 38.0 35.6 0.92 .621
Function Scales
Physical 1 to 5 QLQ-C30 342 29.8 27.2 43.0 341 29.0 25.2 45.7 1.04 .819
Role 6, 7 QLQ-C30 342 33.3 21.9 44.7 342 29.2 21.3 49.4 1.21 .247
Cognitive 20, 25 QLQ-C30 342 29.5 30.4 40.1 339 30.4 26.5 43.1 0.96 .797
Emotional 21 to 24 QLQ-C30 342 30.1 34.2 35.7 340 26.5 32.4 41.2 1.20 .285
Social 26, 27 QLQ-C30 342 34.5 21.9 43.6 340 38.5 21.2 40.3 0.84 .274
Abbreviations: GHS ¼ global health status; OR ¼ odds ratio; QLQ-C30 ¼ Quality of Life Questionnaire C30; QLQ-LC13 ¼ Quality of Life Questionnaire Lung Cancer-13; QoL ¼ quality of life.
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Supplemental Table 2 Correlation Between Missing (Dropout) HRQoL Assessments and Patient Characteristics
Characteristic
Week of
Assessment
Randomized Treatment
Afatinib Erlotinib
n Kendall Tau P n Kendall Tau P
Age, y Baseline 391 0.06 .187 391 0.01 .741
4 353 0.01 .747 354 0.06 .212
8 304 0.06 .208 302 0.02 .653
12 236 0.01 .832 221 0.02 .769
20 145 0.00 .997 114 0.08 .292
28 93 0.02 .788 71 0.09 .349
36 46 0.04 .759 42 0.26 .050
44 39 0.00 .973 24 0.15 .386
52 30 0.15 .335 18 0.02 .928
ECOG Performance
Status (0, 1)
Baseline 391 0.11 .025 391 0.14 .006
4 353 0.10 .073 354 0.11 .037
8 304 0.13 .019 302 0.04 .448
12 236 0.06 .342 221 0.03 .606
20 145 0.07 .378 114 0.01 .931
28 93 0.10 .344 71 0.00 .989
36 46 0.09 .539 42 0.11 .468
44 39 0.04 .814 24 0.20 .328
52 30 0.11 .554 18 0.24 .322
Race (Non-Eastern
Asian/Eastern Asian)
Baseline 391 0.11 .032 391 0.02 .662
4 353 0.01 .782 354 0.07 .200
8 304 0.01 .887 302 0.05 .355
12 236 0.00 .955 221 0.09 .167
20 145 0.04 .631 114 0.00 .969
28 93 0.06 .578 71 0.13 .295
36 46 0.05 .756 42 0.20 .209
44 39 0.01 .945 24 0.17 .404
52 30 0.01 .977 18 0.08 .740
Sex (Male/Female) Baseline 391 0.02 .663 391 0.04 .391
4 353 0.08 .112 354 0.01 .879
8 304 0.05 .387 302 0.10 .088
12 236 0.04 .548 221 0.00 .997
20 145 0.00 .987 114 0.05 .593
28 93 0.06 .553 71 0.03 .815
36 46 0.06 .705 42 0.17 .277
44 39 0.13 .432 24 0.26 .216
52 30 0.16 .376 18 0.40 .103
Abbreviations: ECOG ¼ Eastern Cooperative Oncology Group; HRQoL ¼ health-related quality of life.
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Supplemental Table 3 Correlation Between Missing (Dropout)
HRQoL Assessments and Randomized
Treatment
Week of
Assessment n Kendall’s Tau P
0 782 0.00 .903
4 707 0.01 .759
8 606 0.05 .203
12 457 0.10 .034
20 259 0.02 .759
28 164 0.10 .219
36 88 0.31 .004
44 63 0.02 .863
52 48 0.04 .765
Abbreviation: HRQoL ¼ health-related quality of life.
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Supplemental Table 4 Correlation Between Missing (Dropout) Assessments, and Baseline GHS/QoL and Symptom Assessments
Week of Assessment
Afatinib Erlotinib
n Kendall’s Tau P n Kendall’s Tau P
Correlation Between Baseline GHS/QoL
Assessment and Missing (Dropout) GHS/
QoL Assessments
0 380 0.17 <.001 376 0.11 .018
4 339 0.14 .004 339 0.09 .065
8 294 0.08 .135 287 0.13 .012
12 229 0.15 .009 210 0.12 .040
20 140 0.13 .087 109 0.18 .033
28 90 0.01 .877 69 0.06 .553
36 45 0.14 .281 41 0.03 .811
44 38 0.24 .092 23 0.08 .669
52 28 0.39 .022 17 0.24 .274
Correlation Between Baseline Cough
Assessment and Missing (Dropout) Cough
Assessments
0 380 0.04 .360 377 0.01 .848
4 339 0.02 .677 341 0.06 .236
8 295 0.01 .858 287 0.04 .524
12 228 0.04 .546 210 0.04 .523
20 141 0.08 .338 111 0.15 .100
28 91 0.02 .802 69 0.10 .376
36 46 0.07 .593 41 0.09 .571
44 39 0.18 .242 23 0.16 .431
52 29 0.08 .646 17 0.07 .786
Correlation Between Baseline Dyspnea
Assessment and Missing (Dropout)
Dyspnea Assessments
0 380 0.15 <.001 376 0.09 .036
4 339 0.02 .700 340 0.15 .001
8 296 0.02 .691 286 0.18 <.001
12 229 0.07 .224 209 0.09 .128
20 141 0.11 .152 110 0.07 .400
28 92 0.01 .914 69 0.11 .297
36 46 0.11 .389 41 0.11 .425
44 39 0.03 .857 23 0.12 .543
52 29 0.14 .404 17 0.10 .653
Correlation Between Baseline Pain
Assessment and Missing (Dropout) Pain
Assessments
0 383 0.15 .001 378 0.09 .062
4 343 0.13 .007 342 0.11 .030
8 297 0.05 .334 290 0.14 .009
12 231 0.05 .387 211 0.09 .149
20 143 0.18 .017 111 0.17 .044
28 92 0.02 .803 69 0.16 .159
36 46 0.01 .935 41 0.01 .954
44 39 0.15 .302 22 0.29 .155
52 29 0.30 .080 17 0.02 .917
Abbreviations: GHS ¼ global health status; QoL ¼ quality of life.
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Supplemental Table 5 Mean Score to Truncation Time for GHS/QoL and Symptoms From the Joint Model
Dropout Event
Afatinib Erlotinib Difference (Afatinib L Erlotinib)
Mean SE Mean SE Mean SE
GHS/QoL
None (primary analysis) 59.287 0.794 57.333 0.795 1.953 0.910
Treatment termination (censoreda) 58.573 0.808 56.657 0.808 1.916 0.914
Last assessment (uncensored) 58.767 0.810 56.829 0.810 1.937 0.921
Last assessment (censoreda) 58.770 0.810 56.802 0.810 1.968 0.921
Cough
None (primary analysis) 35.410 1.030 39.007 1.031 3.597 1.174
Treatment termination (censoreda) 35.715 1.032 39.298 1.034 3.583 1.173
Last assessment (uncensored) 35.605 1.032 39.219 1.033 3.614 1.175
Last assessment (censoreda) 35.605 1.032 39.238 1.034 3.633 1.175
Dyspnea
None (primary analysis) 27.697 0.870 30.947 0.872 3.250 0.956
Treatment termination (censoreda) 28.242 0.880 31.469 0.881 3.228 0.957
Last assessment (uncensored) 28.100 0.884 31.351 0.885 3.251 0.964
Last assessment (censoreda) 28.088 0.882 31.366 0.884 3.278 0.964
Pain
None (primary analysis) 26.735 1.076 29.459 1.078 2.724 1.192
Treatment termination (censoreda) 27.886 1.102 30.509 1.100 2.623 1.206
Last assessment (uncensored) 27.617 1.108 30.241 1.105 2.624 1.216
Last assessment (censoreda) 27.596 1.107 30.265 1.105 2.668 1.216
Results from the longitudinal model (adjusting for race).
Abbreviations: GHS ¼ global health status; QoL ¼ quality of life; SE ¼ standard error.
aCensored: at database lock date.
Supplemental Table 6 Mean Score to Truncation Time of 12 Weeks for GHS/QoL and Symptoms From the Pattern-Mixture Model
Model Extrapolation
Afatinib Erlotinib Difference (Afatinib L Erlotinib)
Mean SE Mean SE Mean SE
GHS/QoL
Primary analysis NA 59.287 0.794 57.333 0.795 1.953 0.910
Pattern mixture LMCF 59.374 0.846 57.865 0.848 1.508 1.116
Nearest neighbor 58.462 0.866 57.113 0.869 1.349 1.146
Cough
Primary analysis NA 35.410 1.030 39.007 1.031 3.597 1.174
Pattern mixture LMCF 34.638 1.137 39.946 1.140 5.307 1.466
Nearest neighbor 34.982 1.161 39.682 1.168 4.700 1.505
Dyspnea
Primary analysis NA 27.697 0.870 30.947 0.872 3.250 0.956
Pattern mixture LMCF 27.298 0.907 30.193 0.910 2.895 1.114
Nearest neighbor 28.031 0.925 31.136 0.932 3.105 1.144
Pain
Primary analysis NA 26.735 1.076 29.459 1.078 2.724 1.192
Pattern mixture LMCF 26.432 1.089 27.984 1.091 1.552 1.367
Nearest neighbor 27.081 1.114 29.074 1.118 1.993 1.407
Results from the longitudinal model (adjusting for race).
Abbreviations: GHS/QoL ¼ global health status/quality of life; LMCF ¼ last mean carried forward; SE ¼ standard error.
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Supplemental Table 7 Improvement in Individual Items of QLQ-C30 and QLQ-LC13
Question
Afatinib Erlotinib
OR Pn
Improved
(%)
Stable
(%)
Worsened
(%) n
Improved
(%)
Stable
(%)
Worsened
(%)
Individual Items, QLQ-C30
Trouble strenuous activities 1 340 37.1 24.1 38.8 340 35.3 25.6 39.1 1.08 .632
Trouble long walk 2 341 32.8 27.6 39.6 342 34.8 24.6 40.6 0.92 .595
Trouble short walk 3 336 18.8 38.7 42.6 338 20.4 33.4 46.2 0.9 .586
Stay in bed 4 342 21.3 37.4 41.2 341 26.1 30.2 43.7 0.77 .141
Trouble eat dress 5 341 4.4 70.4 25.2 341 5.6 66.3 28.2 0.78 .481
Trouble daily activities 6 341 29.3 28.7 41.9 341 24.6 26.4 49 1.27 .165
Trouble leisure activities 7 341 22.3 32.6 45.2 341 23.8 28.4 47.8 0.92 .651
Short of breath 8 340 35.3 28.8 35.9 342 31 29.8 39.2 1.21 .234
Have pain 9 342 32.2 28.4 39.5 342 36 24.6 39.5 0.84 .297
Need to rest 10 341 34 23.8 42.2 341 33.1 22.6 44.3 1.04 .806
Insomnia 11 341 30.8 31.1 38.1 342 28.1 31 40.9 1.14 .432
Felt weak 12 340 31.2 23.5 45.3 341 24.6 26.4 49 1.38 .058
Appetite loss 13 341 24.9 26.4 48.7 342 25.1 23.4 51.5 0.99 .947
Nauseated 14 342 17.3 48 34.8 341 14.4 47.2 38.4 1.24 .304
Vomited 15 342 6.7 70.2 23.1 342 7.6 68.1 24.3 0.88 .657
Constipation 16 341 27 48.4 24.6 342 31.9 40.9 27.2 0.79 .161
Diarrhea 17 342 8.5 14.3 77.2 339 5.6 40.4 54 1.56 .146
Tired 18 337 32.3 28.2 39.5 338 29.6 24.3 46.2 1.14 .436
Pain affecting daily activities 19 340 27.1 32.9 40 337 27.6 31.8 40.7 0.97 .88
Trouble concentrating 20 342 15.8 50.3 33.9 337 14.5 42.1 43.3 1.1 .651
Felt tense 21 341 28.2 35.5 36.4 339 24.5 35.7 39.8 1.21 .273
Worried 22 340 32.4 34.4 33.2 339 31 31.9 37.2 1.07 .684
Irritable 23 340 28.5 37.9 33.5 338 23.7 35.5 40.8 1.29 .149
Depressed 24 340 24.7 39.1 36.2 339 22.7 39.8 37.5 1.12 .54
Trouble remembering 25 339 23.9 45.4 30.7 339 25.7 40.4 33.9 0.9 .576
Family life affected 26 342 27.2 33.3 39.5 340 28.2 30.9 40.9 0.95 .758
Social life affected 27 340 25.6 31.2 43.2 338 27.8 29.9 42.3 0.89 .512
Financial difﬁculties 28 341 28.4 46.6 24.9 337 23.4 46 30.6 1.3 .139
Overall health rate 29 339 43.4 13 43.7 338 35.8 14.8 49.4 1.37 .045
Quality of life rate 30 339 43.1 12.1 44.8 339 36.0 13.9 50.1 1.34 .060
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Supplemental Table 7 Continued
Question
Afatinib Erlotinib
OR Pn
Improved
(%)
Stable
(%)
Worsened
(%) n
Improved
(%)
Stable
(%)
Worsened
(%)
Individual Items, QLQ-LC13
Coughing 1 339 43.4 25.4 31.3 341 35.2 29.3 35.5 1.41 .029
Hemoptysis 2 339 10 65.8 24.2 341 11.1 63.6 25.2 0.89 .628
Dyspnea rested 3 339 22.4 46.6 31 341 22 41.9 36.1 1.02 .897
Dyspnea walked 4 338 34.6 28.4 37 340 26.5 31.5 42.1 1.47 .022
Dyspnea climbed stairs 5 337 34.7 30.6 34.7 338 33.1 28.7 38.2 1.07 .663
Sore mouth 6 338 5.6 33.7 60.7 341 8.8 53.7 37.5 0.62 .113
Dysphagia 7 340 8.8 53.2 37.9 340 10 58.8 31.2 0.87 .598
Peripheral neuropathy 8 340 27.4 40.6 32.1 341 25.2 38.7 36.1 1.12 .528
Alopecia 9 339 18.9 54 27.1 339 22.4 51.6 26 0.8 .245
Pain in chest 10 337 29.1 41.8 29.1 341 26.7 40.5 32.8 1.13 .489
Pain in arm or shoulder 11 337 25.2 43.9 30.9 339 32.2 39.8 28 0.71 .047
Pain in other parts 12 328 24.7 39.9 35.4 326 26.4 38 35.6 0.92 .621
Abbreviations: OR ¼ odds ratio; QLQ-C30 ¼ Quality of Life Questionnaire C30; QLQ-LC13 ¼ Quality of Life Questionnaire Lung Cancer-13.
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Supplemental Table 8 Diarrhea Substudy
Afatinib, n [ 36 Erlotinib, n [ 27
Incidence of Diarrhea, n (%)
Any 31 (86.1) 14 (51.8)
CTCAE Grade 2 16 (44.4) 4 (14.8)
CTCAE Grade 3 7 (19.4) 0 (0.0)
CTCAE Grade 4 0 (0.0) 0 (0.0)
Median Duration of Diarrhea, d (Range)
Any 23 (2-79) 5.5 (1-32)
CTCAE Grade 2 5.5 (1-28) 8.5 (1-24)
CTCAE Grade 3 3 (2-10) e
Dose Reductions Because of Diarrhea, n (%) 7 (19.4) 1 (3.7)
Median Duration of Diarrhea After Dose Reduction, d (Range) 13 (3-43) 3 (3-3)
Treatment Discontinuations Because of Diarrhea, n (%) 0 (0.0) 0 (0.0)
Duration of First Episode of Diarrhea
Median, d (range) 6 (1-74) 1 (1-27)
2 d, n (%) 11 (30.6) 10 (37.0)
3 to 5 d, n (%) 4 (11.1) 2 (7.4)
6 to 7 d, n (%) 3 (8.3) 0 (0.0)
7 d, n (%) 13 (36.1) 2 (7.4)
Abbreviation: CTCAE ¼ Common Terminology Criteria for Adverse Events.
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